Ampio Pharmaceuticals Inc

Ampio Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm engages in the development of therapies to treat prevalent inflammatory conditions. Its product pipeline includes new uses for approved drugs and new molecular entities for important therapeutic areas, including metabolic disease, eye disease, kidney disease, inflammation and sexual dysfunction and CNS disease. The company was founded by David Bar-Or in December 2008 and is headquartered in Englewood, CO.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ampio Pharmaceuticals, Inc. (AMPE) CEO Mike Macaluso on Q1 2021 Results - Earnings Call Transcript

ENGLEWOOD, Colo., May 5, 2021 /PRNewswire/ --  Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for which there are limited treatment options, today reported quarterly financial results for the first quarter period ended March 31, 2021, and provided a corporate overview and business update.

Ampio Pharmaceuticals, Inc. Reports First Quarter 2021 Financial Results and Provides Business Update

Ampio Pharmaceuticals Inc (NYSE: AMPE) revealed positive results from its AP-014 Phase 1 trial utilizing inhaled Ampion in treating respiratory distress in COVID-19 patients.  The study met its primary endpoint and showed an even greater improvement in all-cause mortality over patients treated using Standard of Care (SOC) than initially reported.

Ampio Pharma's Inhaled COVID-19 Treatment Shows 78% Improvement In All-Cause Mortality

ENGLEWOOD, Colo., April 27, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today revealed positive results in its AP-014 Phase I clinical trial utilizing inhaled Ampion in treating respiratory distress in patients as a result of COVID-19.

Ampion™ Reduces All-cause Mortality in COVID-19 Respiratory Distress by Nearly 80%

ENGLEWOOD, Colo., April 27, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced that it had received a positive response from the U.S. Food and Drug Administration (FDA) on its plans for its AP-013 Phase III trial for the intra-articular injection of Ampion™, its novel anti-inflammatory, for patients suffering from severe osteoarthritis of the knee (OAK).

Ampio Pharmaceuticals Provides Updates on Clinical Programs for Ampion™ in Osteoarthritis and COVID-19

ENGLEWOOD, Colo., April 21, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced it will host a conference call to discuss financial results for the quarter ended March 31, 2021 and provide a corporate business update on Wednesday, May 5, 2021 at 4:30pm EDT/ 2:30pm MT.

Ampio Pharmaceuticals, Inc. to Report Fiscal 2021 First Quarter Financial Results and Provide Corporate Business Update

ENGLEWOOD, Colo., April 19, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for which there are limited treatment options, today announced findings of pre-clinical research demonstrating that Ampio's lead drug candidate, Ampion™, provides some of the same anti-inflammatory effects as the steroid dexamethasone but without the significant adverse events associated with steroids.

Research Shows Ampion™ Gene Regulation Mimics the Anti-Inflammatory Effects of Steroids, but without Adverse Effects

ENGLEWOOD, Colo., April 6, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced the results of a pre-clinical study demonstrating that Ampion inhibits an important pro-inflammatory pathway in the types of immune cells implicated in COVID-19 and Lupus Nephritis.

Ampio Pharmaceuticals' Study Shows Ampion Inhibits a Key Inflammatory Pathway in COVID-19 and Lupus Nephritis

Ampio Pharmaceuticals (NYSE American: AMPE), a clinical stage biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, presented March 24, 2021 at the Benzinga Biotech Small Cap Conference. By Mark Gilman

Ampio Pharmaceuticals is Building on its Progress in Tackling Osteoarthritis and COVID-19 Respiratory Issues

ENGLEWOOD, Colo., March 29, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a clinical stage biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced the company will present its findings on a poster entitled, "Regulatory decisions during COVID-19: Efficient nonclinical inhalation toxicology for a clinical program," at the upcoming 23rd International Congress of the International Society for Aerosols in Medicine (ISAM).

Ampio Pharmaceuticals to Present at the International Society for Aerosols in Medicine (ISAM) 23rd International Congress

ENGLEWOOD, Colo., March 16, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, recently revealed preliminary positive results in its AP-014 Phase I clinical trial utilizing inhaled Ampion in treating respiratory distress in patients as a result of COVID-19.

Ampio Pharmaceuticals Details Early Positive Results for Inhaled Ampion in COVID-19 Respiratory Distress

ENGLEWOOD, Colo., March 10, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced that it has been invited to participate in the 33rd Annual ROTH Growth Conference being held virtually on March 15-17, 2021.

Ampio Pharmaceuticals to Participate in the 33rd Annual Virtual ROTH Conference on March 15-17, 2021

Investors liked what they heard in the company's Q4 update.

Why Ampio Pharmaceuticals Stock Is Jumping Today

The stock price of Ampio Pharmaceuticals Inc (NYSEAMERICAN: AMPE) has increased by over 10% pre-market. This is why it happened.

AMPE Stock Price Increases Over 10% Pre-Market: Why It Happened

Ampio Pharmaceuticals' (AMPE) CEO Mike Macaluso on Q4 2020 Results - Earnings Call Transcript

ENGLEWOOD, Colo., March 3, 2021 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced that management will present at the virtual H.C....

Ampio Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference

ENGLEWOOD, Colo., Feb. 24, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced it will host a conference call to discuss the financial...

Ampio Pharmaceuticals, Inc. to Report Annual 2020 Financial Results and Provide Corporate Business Update

Ampio Pharmaceuticals, Inc. is a non-revenue producing biopharmaceutical company aiming to develop immunology-based therapies for inflammatory conditions. Ampio's pipeline consists of one late-stage therapeutic ("Ampion") across six inflammatory indications. Ampion is a novel biologic drug that regulates immune responses by suppressing inflammatory cytokines (proteins) and activating anti-inflammatory cytokines(tissue repair).

Ampio: Short-Term Triple-Digit Upside From Ampion's Progressing Phase 3 Drug Application

Investors weren't comfortable with FDA feedback on the company's late-stage clinical trial.

Why Ampio Pharmaceuticals Stock Tanked Today

Blink Charging

Denali Therapeutics

MongoDB

2020 is almost over. Maybe it's time to cash in -- and cash out?

Why MongoDB, Blink Charging, Ampio Pharmaceuticals, and Denali Therapeutics Stocks Tanked Today

Investors need to pay close attention to Ampio Pharmaceuticals (AMPE) stock based on the movements in the options market lately.

Implied Volatility Surging for Ampio Pharmaceuticals (AMPE) Stock Options

Investors need to pay close attention to Ampio (AMPE) stock based on the movements in the options market lately.

Do Options Traders Know Something About Ampio (AMPE) Stock We Don't?

Ampio Pharmaceuticals, Inc. (AMPE) CEO on Q3 2020 Earnings Results - Conference Call Transcript

Great Panther Silver

Gulfport Energy Corp

Ferroglobe

Matinas BioPharma Hlds

Turquoise Hill Resources

Tanzanian Royalty Exploration

If you're itching for a little excitement in your investing, these cheap stocks under $1 might be just what you're looking for. The post 7 Cheap Stocks Under $1 That Deserve A Second Look appeared first on InvestorPlace.

7 Cheap Stocks Under $1 That Deserve A Second Look

Ampio’s delayed pivotal phase 3 trial for severe OAK to resume.

News for Ampio Pharmaceuticals Inc Stock (AMPE)